Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8+ T cells during vaccine immunotherapy

Takeda, Yohei; Azuma, Masahiro; Matsumoto, Misako; Seya, Tsukasa

Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8+ T cells during vaccine immunotherapy

Takeda, Yohei; Azuma, Masahiro; Matsumoto, Misako et al.

Journal of experimental & clinical cancer research, 2016, 35, 143

Permalink : https://hdl.handle.net/2115/63749

このアイテムのアクセス数:1,199件（2026-10-13 16:45 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
art_10.1186_s13046-016-0416-x	pdf	1.50 MB	818

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/63749
タイトル	Tumoricidal efficacy coincides with CD11c up-regulation in antigen-specific CD8+ T cells during vaccine immunotherapy
著者	Takeda, Yohei ; Azuma, Masahiro ; Matsumoto, Misako ; Seya, Tsukasa
著者名 Takeda, Yohei
著者名 Azuma, Masahiro
e-Rad_Researcher 30332456 著者名 Matsumoto, Misako
e-Rad_Researcher 10301805 著者名 Seya, Tsukasa
言語	英語
キーワード	CTL
	CD11c+ CD8+ T cell
	Adjuvant
	Poly(I:C)
	TLR3
	Antitumor immunotherapy
	Therapeutic marker
発行日	2016-09-13
出版者	BioMed Central
収録物名	Journal of experimental & clinical cancer research
巻(号)	35
ページ	143
抄録	Background: Dendritic cells (DCs) mount tumor-associated antigens (TAAs), and the double-stranded RNA adjuvant Poly(I:C) stimulates Toll-like receptor 3 (TLR3) signal in DC, which in turn induces type I interferon (IFN) and interleukin-12 (IL-12), then cross-primes cytotoxic T lymphocytes (CTLs). Proliferation of CTLs correlates with tumor regression. How these potent cells expand with high quality is crucial to the outcome of CTL therapy. However, good markers reflecting the efficacy of DC-target immunotherapy have not been addressed. Methods: Using an EG7 (ovalbumin, OVA-positive) tumor-implant mouse model, we examined what is a good marker for active CTL induction in treatment with Poly(I:C)/OVA. Results: Simultaneous administration of Poly(I:C) and antigen (Ag) OVA significantly increased a minor population of CD8+ T cells, that express CD11c in lymphoid and tumor sites. The numbers of the CD11c+ CD8+ T cells correlated with those of induced Ag-specific CD8+ T cells and tumor regression. The CD11c+ CD8+ T cell moiety was characterized by its high killing activity and IFN-γ-producing ability, which represent an active phenotype of the effector CTLs. Not only a TLR3-specific (TICAM-1-dependent) signal but also TLR2 (MyD88) signal in DC triggered the expansion of CD11c+ CD8+ T cells in tumor-bearing mice. Notably, human CD11c+ CD8+ T cells also proliferated in peripheral blood mononuclear cells (PBMC) stimulated with cytomegalovirus (CMV) Ag. Conclusions: CD11c expression in CD8+ T cells reflects anti-tumor CTL activity and would be a marker for immunotherapeutic efficacy in mouse models and probably cancer patients as well.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution 4.0 International
PISSN	1756-9966
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1186/s13046-016-0416-x